Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 19 | 2022 | 64 | 3.140 |
Why?
|
| Glaucoma, Open-Angle | 11 | 2018 | 50 | 2.170 |
Why?
|
| Visual Fields | 19 | 2018 | 51 | 2.010 |
Why?
|
| Ophthalmology | 4 | 2023 | 27 | 2.000 |
Why?
|
| Optic Disk | 16 | 2014 | 26 | 1.670 |
Why?
|
| Intraocular Pressure | 25 | 2022 | 73 | 1.660 |
Why?
|
| Glaucoma Drainage Implants | 5 | 2020 | 5 | 1.490 |
Why?
|
| Trabeculectomy | 5 | 2022 | 9 | 1.310 |
Why?
|
| Vision Disorders | 13 | 2013 | 69 | 1.180 |
Why?
|
| Optic Nerve Diseases | 10 | 2014 | 18 | 1.120 |
Why?
|
| Cornea | 5 | 2018 | 35 | 1.090 |
Why?
|
| Eye Injuries | 2 | 2023 | 13 | 0.990 |
Why?
|
| Domestic Violence | 2 | 2023 | 40 | 0.970 |
Why?
|
| Cataract | 2 | 2022 | 54 | 0.890 |
Why?
|
| Contusions | 1 | 2023 | 10 | 0.790 |
Why?
|
| Tomography, Optical Coherence | 8 | 2018 | 235 | 0.660 |
Why?
|
| Ophthalmologists | 1 | 2020 | 4 | 0.640 |
Why?
|
| Medicare Part B | 1 | 2020 | 11 | 0.640 |
Why?
|
| Internet | 1 | 2023 | 467 | 0.630 |
Why?
|
| Reimbursement, Incentive | 1 | 2020 | 29 | 0.630 |
Why?
|
| Cultural Diversity | 1 | 2021 | 54 | 0.630 |
Why?
|
| Minority Groups | 1 | 2021 | 141 | 0.600 |
Why?
|
| Faculty, Medical | 1 | 2021 | 200 | 0.580 |
Why?
|
| Motivation | 1 | 2020 | 296 | 0.530 |
Why?
|
| Optic Atrophy | 3 | 2011 | 6 | 0.530 |
Why?
|
| Cross-Sectional Studies | 14 | 2023 | 2701 | 0.510 |
Why?
|
| Retrospective Studies | 17 | 2023 | 6872 | 0.470 |
Why?
|
| Visual Field Tests | 15 | 2016 | 24 | 0.460 |
Why?
|
| Sclera | 4 | 2012 | 10 | 0.420 |
Why?
|
| Aged | 25 | 2023 | 14965 | 0.410 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 102 | 0.410 |
Why?
|
| Male | 39 | 2023 | 31047 | 0.410 |
Why?
|
| Exfoliation Syndrome | 4 | 2016 | 9 | 0.400 |
Why?
|
| Medicare | 3 | 2023 | 625 | 0.390 |
Why?
|
| United States | 8 | 2023 | 8093 | 0.390 |
Why?
|
| Humans | 49 | 2024 | 65140 | 0.380 |
Why?
|
| Cosmetic Techniques | 2 | 2017 | 13 | 0.370 |
Why?
|
| Blindness | 2 | 2017 | 43 | 0.370 |
Why?
|
| Eye Diseases | 2 | 2024 | 37 | 0.370 |
Why?
|
| Internship and Residency | 2 | 2021 | 800 | 0.360 |
Why?
|
| Choroid | 2 | 2011 | 17 | 0.330 |
Why?
|
| Scotoma | 4 | 2016 | 6 | 0.330 |
Why?
|
| Female | 33 | 2024 | 34018 | 0.320 |
Why?
|
| Middle Aged | 29 | 2023 | 18273 | 0.320 |
Why?
|
| Clinical Competence | 1 | 2015 | 726 | 0.310 |
Why?
|
| Pterygium | 1 | 2009 | 1 | 0.300 |
Why?
|
| Conjunctiva | 1 | 2009 | 6 | 0.300 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 2483 | 0.290 |
Why?
|
| Retina | 1 | 2010 | 132 | 0.290 |
Why?
|
| Anterior Chamber | 1 | 2008 | 4 | 0.290 |
Why?
|
| Keratitis, Dendritic | 1 | 2008 | 1 | 0.290 |
Why?
|
| Health Expenditures | 2 | 2020 | 121 | 0.290 |
Why?
|
| Foreign-Body Migration | 1 | 2008 | 24 | 0.290 |
Why?
|
| Retinal Hemorrhage | 4 | 2014 | 7 | 0.280 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 82 | 0.280 |
Why?
|
| Nerve Fibers | 4 | 2014 | 31 | 0.280 |
Why?
|
| Retinal Ganglion Cells | 4 | 2014 | 30 | 0.270 |
Why?
|
| Low Tension Glaucoma | 3 | 2014 | 5 | 0.260 |
Why?
|
| Disease Progression | 11 | 2013 | 1220 | 0.260 |
Why?
|
| Retrobulbar Hemorrhage | 1 | 2006 | 1 | 0.250 |
Why?
|
| Blepharoplasty | 1 | 2006 | 7 | 0.250 |
Why?
|
| Tonometry, Ocular | 10 | 2012 | 20 | 0.250 |
Why?
|
| Adult | 17 | 2023 | 17358 | 0.230 |
Why?
|
| Antihypertensive Agents | 4 | 2014 | 179 | 0.220 |
Why?
|
| Elasticity | 2 | 2018 | 45 | 0.220 |
Why?
|
| Prospective Studies | 11 | 2018 | 3308 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 875 | 0.210 |
Why?
|
| Aged, 80 and over | 11 | 2018 | 5614 | 0.210 |
Why?
|
| Maternal Exposure | 1 | 2024 | 43 | 0.200 |
Why?
|
| Eye | 1 | 2024 | 59 | 0.200 |
Why?
|
| Clothing | 1 | 2003 | 6 | 0.200 |
Why?
|
| Neck | 1 | 2003 | 46 | 0.200 |
Why?
|
| Schools | 1 | 2023 | 169 | 0.190 |
Why?
|
| Evoked Potentials, Visual | 2 | 2011 | 13 | 0.170 |
Why?
|
| Software | 1 | 2023 | 400 | 0.160 |
Why?
|
| Schools, Medical | 1 | 2021 | 150 | 0.150 |
Why?
|
| Ocular Hypertension | 3 | 2014 | 10 | 0.150 |
Why?
|
| Prescription Drugs | 1 | 2020 | 49 | 0.150 |
Why?
|
| Sex Factors | 1 | 2022 | 992 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 164 | 0.140 |
Why?
|
| Genetic Vectors | 1 | 2024 | 918 | 0.140 |
Why?
|
| Anterior Eye Segment | 1 | 2018 | 6 | 0.140 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 1149 | 0.140 |
Why?
|
| Students, Medical | 1 | 2021 | 263 | 0.130 |
Why?
|
| Rhytidoplasty | 1 | 2017 | 2 | 0.130 |
Why?
|
| Platelet-Rich Plasma | 1 | 2017 | 3 | 0.130 |
Why?
|
| Ophthalmic Artery | 1 | 2017 | 6 | 0.130 |
Why?
|
| Device Approval | 1 | 2017 | 13 | 0.130 |
Why?
|
| Genetic Therapy | 1 | 2024 | 839 | 0.130 |
Why?
|
| Equipment Safety | 1 | 2017 | 26 | 0.130 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2017 | 26 | 0.130 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2017 | 67 | 0.130 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 90 | 0.120 |
Why?
|
| Supine Position | 1 | 2016 | 34 | 0.120 |
Why?
|
| Vision Tests | 1 | 2016 | 9 | 0.120 |
Why?
|
| Gonioscopy | 3 | 2012 | 3 | 0.120 |
Why?
|
| Equipment Design | 1 | 2017 | 363 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2018 | 489 | 0.110 |
Why?
|
| Algorithms | 4 | 2011 | 1050 | 0.100 |
Why?
|
| Visual Acuity | 3 | 2013 | 134 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2011 | 1326 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 347 | 0.090 |
Why?
|
| Retinal Artery | 1 | 2011 | 2 | 0.090 |
Why?
|
| Ciliary Arteries | 1 | 2011 | 2 | 0.090 |
Why?
|
| Retinal Vein | 1 | 2011 | 5 | 0.090 |
Why?
|
| Pliability | 1 | 2011 | 6 | 0.090 |
Why?
|
| Refraction, Ocular | 1 | 2011 | 8 | 0.090 |
Why?
|
| Refractive Errors | 1 | 2011 | 13 | 0.090 |
Why?
|
| Iridocorneal Endothelial Syndrome | 1 | 2011 | 1 | 0.090 |
Why?
|
| Biological Dressings | 1 | 2011 | 4 | 0.090 |
Why?
|
| Amnion | 1 | 2011 | 9 | 0.090 |
Why?
|
| Fovea Centralis | 1 | 2011 | 15 | 0.090 |
Why?
|
| Young Adult | 7 | 2020 | 4809 | 0.080 |
Why?
|
| Electroencephalography | 1 | 2011 | 156 | 0.080 |
Why?
|
| Compliance | 1 | 2010 | 5 | 0.080 |
Why?
|
| Risk Factors | 6 | 2014 | 5429 | 0.080 |
Why?
|
| Atrophy | 1 | 2010 | 87 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 706 | 0.080 |
Why?
|
| Bevacizumab | 1 | 2009 | 60 | 0.070 |
Why?
|
| Keratitis, Herpetic | 1 | 2009 | 11 | 0.070 |
Why?
|
| Fluorescein | 1 | 2008 | 13 | 0.070 |
Why?
|
| Cataract Extraction | 1 | 2009 | 36 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 234 | 0.070 |
Why?
|
| Surgical Flaps | 1 | 2008 | 117 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2008 | 202 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 250 | 0.060 |
Why?
|
| Blepharoptosis | 1 | 2006 | 7 | 0.060 |
Why?
|
| Photography | 3 | 2013 | 42 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2011 | 5792 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2016 | 149 | 0.050 |
Why?
|
| Macula Lutea | 1 | 2004 | 26 | 0.050 |
Why?
|
| ROC Curve | 2 | 2016 | 292 | 0.050 |
Why?
|
| Pressure | 1 | 2003 | 78 | 0.050 |
Why?
|
| Adolescent | 4 | 2020 | 6297 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 2244 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2003 | 130 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 1698 | 0.050 |
Why?
|
| Benzoates | 1 | 2022 | 8 | 0.040 |
Why?
|
| beta-Alanine | 1 | 2022 | 8 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2024 | 1422 | 0.040 |
Why?
|
| Dependovirus | 1 | 2024 | 751 | 0.030 |
Why?
|
| Medical Device Recalls | 1 | 2017 | 2 | 0.030 |
Why?
|
| Product Labeling | 1 | 2017 | 9 | 0.030 |
Why?
|
| Injections | 1 | 2017 | 84 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 128 | 0.030 |
Why?
|
| Pregnancy | 1 | 2024 | 2372 | 0.030 |
Why?
|
| Corneal Pachymetry | 1 | 2016 | 1 | 0.030 |
Why?
|
| Animals | 2 | 2024 | 21345 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 72 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2016 | 77 | 0.030 |
Why?
|
| China | 1 | 2015 | 176 | 0.030 |
Why?
|
| Brimonidine Tartrate | 1 | 2014 | 2 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2015 | 118 | 0.030 |
Why?
|
| Timolol | 1 | 2014 | 3 | 0.030 |
Why?
|
| Child | 1 | 2023 | 4607 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2014 | 37 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 883 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2014 | 95 | 0.020 |
Why?
|
| Nigeria | 1 | 2012 | 11 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1163 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1113 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 3762 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 236 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 252 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 262 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 739 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 740 | 0.020 |
Why?
|
| Subarachnoid Space | 1 | 2011 | 15 | 0.020 |
Why?
|
| Pupil Disorders | 1 | 2011 | 4 | 0.020 |
Why?
|
| Diplopia | 1 | 2011 | 8 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2014 | 526 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2011 | 68 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 327 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 298 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2011 | 293 | 0.020 |
Why?
|
| Phacoemulsification | 1 | 2010 | 8 | 0.020 |
Why?
|
| Mitomycin | 1 | 2010 | 27 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 405 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 602 | 0.020 |
Why?
|
| Hypertension | 1 | 2015 | 612 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 1656 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 754 | 0.020 |
Why?
|
| Prednisolone | 1 | 2009 | 11 | 0.020 |
Why?
|
| Eyelid Diseases | 1 | 2009 | 5 | 0.020 |
Why?
|
| Acyclovir | 1 | 2009 | 20 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 699 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 2009 | 49 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 1233 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 296 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1445 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 657 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 1015 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2009 | 125 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 371 | 0.020 |
Why?
|
| Wound Healing | 1 | 2009 | 193 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 463 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 166 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 805 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2009 | 321 | 0.010 |
Why?
|
| Body Weights and Measures | 1 | 2004 | 33 | 0.010 |
Why?
|